Investigating immune responses in head and neck cancer patients undergoing advanced radiotherapy

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study focuses on patients with head and neck cancer who have undergone surgery and are receiving postoperative radiotherapy. It aims to collect blood samples to evaluate the immune response following treatment with proton or carbon ion therapy, which are believed to be more effective and less damaging than traditional radiotherapy. The research seeks to understand how these therapies influence inflammation and immune cell activity, which are crucial for tumor development and treatment response. By analyzing these immune parameters, the study hopes to improve treatment strategies for this challenging cancer type.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Patients \> 18 years
* Head and neck cancer: (upper aerodigestive tract, cavum, facial sinus, skull base, brain) operated
* Surgery for complete tumour resection or with microscopic residue R1
* All possible histologies: squamous cell carcinoma, undifferentiated carcinoma of the nasopharyngeal type (UCNT), adenocarcinoma, adenoid cystic carcinoma, chordoma, chondrosarcoma,meningioma other tumours
* Patients undergoing exclusive postoperative radiotherapy with a minimum total dose of 54 Gy of X-ray photon radiation or equivalent proton radiation.
* Patient affiliated to a social security scheme
* Signature of the informed consent before any specific procedure related to the study

Exclusion Criteria:

* Macroscopic postoperative tumour residue R2
* Previous cancer within 5 years (except treated basal cell skin carcinoma and treated cervical cancer).
* Previous radiotherapy (except brachytherapy of the cervix or prostate)
* Chemotherapy or other systemic oncological treatment (cetuximab) concomitant with radiotherapy
* Long-term immunosuppressive or corticosteroid therapy
* Patient deprived of liberty or under guardianship, protected adult
* Patient unable to undergo trial monitoring for geographical, social or psychopathological reasons
* Pregnant or breastfeeding woman
* Emergency situations

Where it's running

• Centre François Baclesse
  Caen, France Recruiting

Study contacts

• Study coordinator: Mathieu CESAIRE, MD
• Email: m.cesaire@baclesse.unicancer.fr
• Phone: +33 (0)2 31 45 50 20

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Phenotype-based Pain Guidance for Head and Neck Cancer-Related Pain (pilot)

  This pilot test sees if tailoring pain treatment to a patient’s pain type can reduce head and neck cancer pain in adults who haven’t started cancer treatment yet.

  Recruiting Phase 2 Shaukat Khanum Memorial Cancer Hospital & Research Centre · Lahore, Punjab Province · NCT07919444

• Airway ultrasound in head and neck cancer patients

  This observational study tests whether neck ultrasound measurements of the airway match CT measurements in adults with maxillofacial cancer undergoing surgery with anesthesia.

  Recruiting at 2 sites University Hospital Dubrava · Zagreb, City of Zagreb and 1 other locations · NCT07910149

• Safe use of metformin and naproxen to help prevent cancer in people with Fanconi anemia

  This study tests whether metformin and naproxen can lower the chance of cancer developing in adults with Fanconi anemia.

  Recruiting at 2 sites Phase 1 Rockefeller University · Minneapolis, Minnesota and 1 other locations · NCT07901959

• Iparomlimab and Tuvonralimab With Cetuximab Before Surgery in Resectable Oral Cancer

  In this phase 2 study, patients with locally advanced, resectable oral squamous cell carcinoma will receive a combination of iparomlimab, tuvonralimab, and cetuximab before surgery to see if the treatment is safe and can shrink tumors.

  Recruiting Phase 2 Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University · Shanghai, Shanghai Municipality · NCT07882888

• SumMET: Targeted radioligand therapy for c-MET–positive solid tumors

  This first‑in‑human study tests the safety and potential effectiveness of a radioligand therapy called [225Ac]Ac-FL-261 in adults with advanced or metastatic solid tumors that overexpress c-MET.

  Recruiting at 2 sites Phase 1/2 Full-Life Technologies UK Limited · Minneapolis, Minnesota and 1 other locations · NCT07873450

• Using Silverlon for head and neck patients with tracheostomies

  This early-phase study tests whether Silverlon dressings can prevent severe skin reactions under tracheostomy collars in adults with head and neck cancer.

  Recruiting Phase 1 State University of New York - Upstate Medical University · Syracuse, New York · NCT07856732

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.